From Differences in Means between Cases and Controls to Risk Stratification: A Business Plan for Biomarker Development

摘要: Researchers developing biomarkers for early detection can determine the potential clinical benefit at stages of development. We provide theoretical background showing quantitative connection between biomarker levels in cases and controls clinically meaningful risk measures, as well a spreadsheet researchers to use their own research. with tools decide whether test is useful, it needs technical improvement, may work only specific populations, or any further development futile. The methods described here apply method that aims estimate disease based on biomarkers, tests, genetics, environment, behavior. Significance: Many efforts go into futile premature testing. In many instances, predictions translational success failure be made early, simply critical analysis case–control data. Our article presents well-established theory form appreciated by researchers. Furthermore, we an interactive links performance characteristics evaluate promise candidates stage. Cancer Discov; 3(2); 148–57. ©2012 AACR .